ArticleNeurourology and urodynamics2025
Composite Failure Associated With Sacrohysteropexy and Sacrocolpopexy With Supracervical Hysterectomy for Advanced Pelvic Organ Prolapse.
Article in Neurourology and urodynamics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesFailures and complications associated with treatments comprising laparoscopic sacrohysteropexy (SHP) for advanced pelvic organ prolapse (POP) are unclear. We compared failure rates associated with SHP and laparoscopic supracervical hysterectomy (SCH)/sacrocolpopexy (SCP) for advanced POP to determine whether they differed.
methodsClinical data of patients who underwent SHP (n = 52) and SCH/SCP (n = 209) were retrospectively examined. Only patients with advanced Pelvic Organ Prolapse Quantification stage III or IV were included. A single surgeon performed the procedures between October 2019 and October 2022. The primary objective was to compare the composite failure (CF) rates of both groups during the first year after surgery. CF was defined as the leading edge of any compartment beyond the hymen, the presence of subjective bulging, or the need for reoperation. The secondary objective was to analyze complications within 30 days and 1 year postoperatively.
resultsCF rates at 1 year were 13.5% and 5.7% with SHP and SCH/SCP, respectively (odds ratio [OR], 2.54; 95% confidence interval [CI], 0.80-7.48; p = 0.072). The 30-day perioperative complication rates were 3.8% and 3.3% with SHP and SCH/SCP, respectively (OR, 0.66; 95% CI, 0.069-3.1). The postoperative complication rates were 1.9% and 4.3% with SHP and SCH/SCP, respectively (OR, 0.44; 95% CI, 0.0097-3.3).
conclusionsComplications associated with SHP for advanced POP did not differ from those associated with SCH/SCP. However, the occurrence of CF was higher with SHP, indicating a potentially clinically meaningful difference. CLINICAL
trial registrationThis retrospective cohort study of human participants performed at Hokusuikai-Kinen Hospital was conducted in accordance with the principles embodied in the Declaration of Helsinki and approved by the Institutional Review Board (approval number 2022-080).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.